Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duker

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Acta Pharmacologica Et Toxicologica|August 1, 1979
Effects of adrenergic beta-blockers and a membrane stabilizing agent on ouabain-induced cardiac arrhythmias in anaesthetized guinea pigsG Aberg, G Adler, G Duker, et al.
Cardiovascular Research|December 1, 1993
Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisationsL Carlsson, C Abrahamsson, B Andersson, et al.
Cardiovascular Research|February 13, 2001
Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potentialG J Amos, C Abrahamsson, G Duker, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?L Carlsson, G J Amos, B Andersson, et al.
Cardiovascular Research|March 1, 1994
Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalantC Abrahamsson, M Palmer, B Ljung, et al.
Pharmacology & Therapeutics|May 14, 2010
Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacologyM K B Jonsson, M A Vos, G Duker, et al.
British Journal of Pharmacology|July 2, 2011
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesL Nalos, R Varkevisser, M K B Jonsson, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Acta Pharmacologica Et Toxicologica|August 1, 1979
Effects of adrenergic beta-blockers and a membrane stabilizing agent on ouabain-induced cardiac arrhythmias in anaesthetized guinea pigsG Aberg, G Adler, G Duker, et al.
Cardiovascular Research|December 1, 1993
Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisationsL Carlsson, C Abrahamsson, B Andersson, et al.
Cardiovascular Research|February 13, 2001
Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potentialG J Amos, C Abrahamsson, G Duker, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?L Carlsson, G J Amos, B Andersson, et al.
Cardiovascular Research|March 1, 1994
Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalantC Abrahamsson, M Palmer, B Ljung, et al.
Pharmacology & Therapeutics|May 14, 2010
Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacologyM K B Jonsson, M A Vos, G Duker, et al.
British Journal of Pharmacology|July 2, 2011
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesL Nalos, R Varkevisser, M K B Jonsson, et al.
Pageof 3